Supplement to the Prospectus regarding invitation to subscribe for shares in Swedish Orphan Biovitrum AB (publ)

Carnegie

Handelsbanken Capital Markets

Table of contents

Important information

The distribution of this Prospectus Supplement (as defined below), the Prospectus and the subscription application may, in some jurisdictions, be unlawful and these documents may not be used for the purpose of, or as part of, an offer or a solicitation of an offer to any person in a jurisdiction where such an offer or solicitation is not allowed or where it would be deemed unlawful to make such an offer or solicitation.

The Prospectus Supplement has not been and will not be registered in any other state or jurisdiction other than Sweden and the Securities may not be offered, sold, pledged or transferred, directly or indirectly, within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the United States Securities Act of 1933.

The Rights Issue is not directed to shareholders domiciled in Australia, Canada, Hong Kong or Japan or to persons whose participation would require additional prospectuses, registration or measures other than those pursuant to Swedish law. Accordingly, the Prospectus Supplement, the Prospectus and the subscription application may not be distributed in any country in which the distribution or the Rights Issue require such measures or would conflict with regulations in such country. Acquisition of Securities in violation of the restrictions described above may be void. Persons into whose possession this Prospectus Supplement may come are required to comply with such restrictions. Any failure to comply with such restrictions may result in a violation of applicable securities regulations.

The Securities have not been registered and will not be registered under the Securities Act and neither under the securities law of any state or other jurisdiction of the United States and may not be offered, sold, taken up, exercised, resold, delivered or transferred, directly or indirectly, within the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any relevant state or other jurisdiction of the United States. There will be no public offer of the Securities in the United States. A notification of subscription of Securities in contravention of the above may be deemed to be invalid.

The Securities have not been approved or disapproved by the "United States Securities and Exchange Commission", any state securities commission in the United States or any other United States regulatory authority, nor have any of the foregoing authorities passed upon or endorsed the merits of the offering of the Securities or the accuracy or adequacy of this document. Any representation to the contrary is a criminal offense in the United States.

The Securities are being offered and sold outside the United States in reliance on Regulation S under the Securities Act. Any offering of the Securities to be made in the United States will be made only to a limited number of existing shareholders who are reasonably believed to be qualified institutional buyers (as defined in Rule 144A under the Securities Act) pursuant to an exemption from registration under the Securities Act in a transaction not involving any public offering and who have signed and sent a so called "investor letter" to the Company. For a description of these and certain further restrictions on offers, sales and transfers of the Securities and the distribution of this Prospectus Supplement and the Prospectus, see section Restrictions on sale and transfer of securities – headline United States in the Prospectus.

Until 40 days after the commencement of the Rights Issue, any offer or sale of Securities within the United States by any dealer (whether or not participating in the Rights Issue) may violate the registration requirements of the Securities Act.

Approval and registration of the Prospectus Supplement does not constitute a guarantee from the Swedish Financial Supervisory Authority that the information in the Prospectus Supplement is accurate or complete. This Prospectus Supplement has been prepared by Sobi and is based on Sobi's own information and sources deemed by Sobi to be reliable. The Prospectus Supplement has been prepared in both a Swedish and an English version. In the event that the versions do not conform, the Swedish version shall take precedence.

The Prospectus supplement may contain forward-looking information. Such information is no guarantee of future outcomes and is associated with inevitable risks and uncertainties. All forward-looking information that can be ascribed to the Company or persons acting on the Company's behalf is subject to the reservations in, or referred to in, the section Forward-looking statements and market data of the Prospectus.

Supplement to the Prospectus regarding invitation to subscribe for shares in Swedish Orphan Biovitrum AB (publ)

This prospectus supplement ("Prospectus Supplement") has been prepared as a result of Sobi's announcement on May 9, 2011 that the EMA has adopted an opinion agreeing to the pediatric investigational plan for the long-lasting, fully-recombinant Factor IX Fc fusion protein (rFIXFc). The press release is included in the Prospectus Supplement.

The Prospectus Supplement represents a supplement to the Prospectus prepared in relation to the invitation to subscribe for shares in Sobi and that was approved and registered by the Swedish Financial Supervisory Authority on May 5, 2011 (Swedish Financial Supervisory Authority's registration number 11-4262) and made public by Sobi on the same day. The Prospectus Supplement must be read in conjunction with the Prospectus in all respects and the definitions used in the Prospectus shall also apply to the Prospectus Supplement. The Prospectus Supplement was approved by the Swedish Financial Supervisory Authority on May 11, 2011 in accordance with Chapter 2 Section 34 of the Swedish Financial Instruments Trading Act (1991:980) (Swedish Financial Supervisory Authority's registration number 11-5009) and was made public by Sobi on the same day.

With the exception of certain customary restrictions relating to securities laws and regulations, the Prospectus and the Prospectus Supplement are available at the Swedish Financial Supervisory Authority's website (www.fi.se), Sobi's website (www.sobi.com), Carnegie's website (www.carnegie.se) and Handelsbanken's website (www.handelsbanken.se/investmentoffer).

Those investors who have applied for or in any other manner consented to the purchase or subscription of Securities covered by the Rights Issue, before the publication of the Prospectus Supplement, are entitled to withdraw their application or consent within five working days from the publication of the Prospectus Supplement. Such withdrawal must be submitted in writing to Carnegie Investment Bank AB, Transaction Support, SE-103 38 Stockholm, Sweden. Investors who have submitted their subscription application through a trustee should contact the trustee regarding withdrawal. Subscriptions that are not withdrawn will remain binding and those subscribers who wish to remain as subscribers do not need to take any further action.

Press release from Sobi on May 9, 2011

FOR IMMEDIATE RELEASE

Biogen Idec Media Contact:
Tracy Vineis
Senior Manager, Public Affairs
+1 (781) 464-3260

Swedish Orphan Biovitrum:
Peter Edman, CSO
Phone: +46 8 629 21 77
peter.edman@sobi.com

Biogen Idec Investor Relations Contact:
Kia Khaleghpour
Associate Director, Investor Relations
+1 (781) 464-2442

BIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM RECEIVE OPINION FROM EMA ON PEDIATRIC PLAN FOR LONG-LASTING HEMOPHILIA B THERAPY

Weston, Mass. and Stockholm, Sweden – May 9, 2011 – Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) today announced that the European Medicines Agency's (EMA) Pediatric Committee (PDCO) has adopted an opinion agreeing to the pediatric investigational plan for the companies' long-lasting, fully-recombinant Factor IX Fc fusion protein (rFIXFc).

In accordance with the PDCO's opinion, Biogen Idec and Swedish Orphan Biovitrum plan to initiate a global pediatric trial in previously-treated patients under 12 years of age as soon as sufficient data are available from a study of older patients. Under draft guidelines published by the EMA for the development of Factor IX products, pediatric data from this trial will be required in the initial submission of a Marketing Authorization Application to the European regulatory agency.

"The EMA's agreement to our pediatric investigational plan is another milestone in our effort to develop innovative therapies for people with hemophilia," said Glenn Pierce, M.D., Ph.D., Senior Vice President of Hemophilia at Biogen Idec. "With this opinion and the ongoing Phase 3 trials of our long-lasting Factor IX and Factor VIII programs, we continue to make progress toward our goal of improving the way hemophilia is treated worldwide."

"The opinion from the EMA's Pediatric Committee is valuable for our promising rFIXFc project, as it allows for the development of rFIXFc in the pediatric population. We are excited about the potential of this innovative product to make a difference in the lives of people with hemophilia," said Peter Edman, Ph.D., Chief Scientific Officer of Swedish Orphan Biovitrum.

About rFIXFc and the recombinant Fc Fusion protein hemophilia program
rFIXFc is a recombinant Factor IX Fc fusion protein developed using monomeric Fc fusion technology. The technology makes use of a natural mechanism that recycles rFIXFc in the circulation to extend its half-life. It is a fully-recombinant clotting factor designed to replace the protein that hemophilia B patients lack and to last longer in the body than commercially-available Factor IX products. rFIXFc is currently being evaluated in a registrational, open-label, multicenter trial (B-LONG) designed to evaluate its safety, pharmacokinetics and efficacy in hemophilia B patients.

Using the same proprietary monomeric Fc fusion technology as rFIXFc, Biogen Idec and Swedish Orphan Biovitrum are also developing a fully-recombinant, long-lasting Factor VIII Fc fusion protein (rFVIIIFc) for the treatment of hemophilia A. rFVIIIFc is currently being evaluated in a registrational, open-label, multicenter trial (A-LONG) designed to evaluate its safety, pharmacokinetics and efficacy in hemophilia A

patients. For more information on the rFIXFc and rFVIIIFc trials, please visit www.biogenidechemophilia.com or www.clinicaltrials.gov.

About Hemophilia B
Hemophilia B is a rare, inherited disorder in which the ability of a person's blood to clot is impaired. Hemophilia B occurs in about one in 25,000 male births annually and is caused by having substantially reduced or no Factor IX protein, which is needed for normal blood clotting. People with hemophilia B therefore need injections of Factor IX to restore the coagulation process and prevent frequent bleeds that could otherwise lead to pain, irreversible joint damage and life-threatening hemorrhages. Prophylactic treatment with infusions twice per week to maintain a sufficient circulating level of coagulation factor is being increasingly used, and long-term studies demonstrate that such regimens increase the patient's life expectancy and greatly reduce, if not eliminate, progressive joint deterioration.

About Biogen Idec
Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than $4 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

About Swedish Orphan Biovitrum (Sobi)
Sobi is a Swedish-based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late-stage clinical development pipeline. Our focus areas are: hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer and inherited metabolic disorders. Sobi had pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visit www.sobi.com.

Safe Harbor
This press release contains forward-looking statements, including statements about the development of long-lasting hemophilia therapies. These statements may be identified by words such as "believe," "expect," "may," "plan," "will" and similar expressions, and are based on the companies' current beliefs and expectation. Drug development involves a high degree of risk. Factors which could cause actual results to differ materially from the companies' current expectations include the risk that we may not fully enroll our planned clinical trials, unexpected concerns may arise from additional data or analysis, regulatory authorities may require additional information, further studies, or may fail to approve the drug, or the companies may encounter other unexpected hurdles. For more detailed information on the risks and uncertainties associated with Biogen Idec's drug development and other activities, see the periodic reports of Biogen Idec filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the companies assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on May 9, 2011, 11:15 a.m. CET.

###